Search | Syneos Health Communications

#1

Learn how to pivot and adapt your commercialization and communications tactics amid COVID-19 with insights from Rich Gorman and Leigh Householder at Syneos Health in this Xtalks webinar.

#2

Though once overwhelmed by the pandemic, many healthcare systems have already restructured themselves after learning critical lessons from COVID-19.

#3

Over the course of the COVID-19 pandemic, information has varied around whether or not – and how severely – children are affected by the virus.

#4

How COVID-19 and 3 other barriers will transform healthcare over the next few years.

#5

Virtual collaboration isn’t the future of work – it's the wave of the present

#6

Best practices for avoiding the novel corona virus are fairly well publicized, but for people who have contracted COVID-19 guidance can be harder to come by.

#7

The Department of Health and Human Services (HHS) has selected the Fors Marsh Group to handle the new $250 million coronavirus campaign.

#8

Meg Alexander, head of the reputation and risk management practice at Syneos Health, and Jeff Stewart, managing director at Syneos Health Consulting, teamed up with MM&M to discuss implications of COVID-19 and the upcoming US election on drug pricing.

#9

The COVID-19 pandemic is steadily increasing our risk for a mental health crisis around the world.

#10

As we continue to navigate these unprecedented times, Syneos Health conducted two surveys during the months of March and May to help us track and understand the impact COVID-19 has had on physicians’ engagement with telemedicine platforms and field force teams.

#11

In this episode in our Coronavirus Special Edition Series, Jodi Scarbrough, Director of Custom Research at Syneos Health, discusses the impact of the COVID-19 on the adoption of telemedicine and teledetailing, and how these platforms might play out post-pandemic.

#12

With the dramatic impact that COVID 19 has had on work, school, social engagements, and overall life as we know it, one would think that people would be anxious to be vaccinated.

#13

In this PM360 article, Steve Marino, Managing Director of Digital & Social Strategy at Syneos Health Communications, shares "guidance (that) can help marketers navigate their way as they make decisions about what types of content to post, and what not to post."

#14

Ten years after acquiring its competitor Duane Reade, Walgreens has set its sights on a whole different type of growth, announcing its plan to establish doctor’s offices in hundreds of its familiar brick-and-mortar stores.

#15

Achieving success in the current global context now hinges on “the virtual meeting” – the most important method for teams to stay connected, troubleshoot, and drive results.

#16

How are payers responding to COVID-19?

#17

The Food and Drug Administration (FDA) has approved the use of Veklury (remdesivir) for use in adult and adolescent patients 12 years of age and older for the treatment of COVID-19 in instances that require hospitalization.

#18

Think Bank is an agile way to answer complex questions.

#19

Life sciences companies have a variety of tools to demonstrate the value of their medicines in the real world, but any innovative agreement or study should definitively answer these five questions.

#20

With an increasing number of coronavirus cases popping up around the world, countries are taking action by leveraging innovative health tech to protect the safety of the public without compromising the care they need.

#21

In this Coronavirus Special Edition Series, we’ve talked a lot about the clinical implications of the COVID-19 pandemic.

#22

Novo Nordisk’s new diabetes drug seemed all set for launch in early 2020, a time nobody could plan for.

#23

Part I of a Syneos Health Series on New Oncology Commercialization Strategies

#24

As the pandemic surged, New York City’s Mt.

#25

What are payers focused on during the COVID-19 pandemic?

#26

Life sciences commercialization in the COVID-19 era and beyond

#27

COVID-19 has accelerated the rate at which we’re seeing change happening around us.

#28

COVID-19 treatment regimens are underscoring the threat of antimicrobial resistance, which threatens to kill as many as 20 million people per year by 2050.

#29

As some people near the end of their third month of lockdown, many COVID-19-related trends are starting to look quite different than they did toward the beginning of the pandemic.

#30

What should the evolution of your digital strategy look like through COVID-19 and beyond?

Search Results

Connect

Site

Search Results

Connect

Site

Subscribe to our RSS feed